Seven of the 10 companies participating in the fall cohorts of MassBio and SCbio’s Drive program are based in the United ...

With M&A rising, venture capital returning and policy risks easing, biotech is on a positive trajectory following a prolonged ...

Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, ...

The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution ...

Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...

Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...

Last month’s FDA advisory committee meetings for therapies developed by Capricor Therapeutics and Replimune effectively ...

The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful ...

With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the ...

New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a ...

In this episode of Denatured, you’ll hear from Christina Takke, managing partner at V-Bio Ventures and Mariette van der ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...